This was particularly noted when intraperitoneal injections of the Nrf2 inhibitor ML385 prior to the administration of protodioscin suppressed the latter’s therapeutic effects in mice with pulmonary fibrosis. Here, NFE2L2 is linked to pulmonary fibrosis.